J Neuroimmunol. 2007 Sep 11; [Epub ahead of print]Click here to read Links
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.
Gladstone DE, Golightly MG, Brannagan TH 3rd.
Hematology Oncology Associates of Western Suffolk, 24 East Main Street, Bay Shore, NY 11706, United States.
INTRODUCTION: T cells occupy a central role in MS and CIDP pathogenesis. High dose cyclophosphamide's in-vivo cytotoxic-effect on circulating memory and naïve T cells is unknown. METHOD: Three MS and five CIDP patients received cyclophosphamide (200 mg/kg) for refractory disease. Before and after chemotherapy administration, peripheral blood T-cell subsets were determined. Patients underwent serial neurologic evaluations quarterly. RESULTS: Cyclophosphamide uniformly decreased clinical disease activity. Compared to memory T cells, naïve T cells were preferentially eradicated. DISCUSSION: Cyclophosphamide effectiveness in autoimmune illness may result from Naïve T-cell destruction, as this compartment may be the source of autoreactive lymphocytes.
PMID: 17854912 [PubMed - as supplied by publisher]
The phase II trial is stopped at Stony Brook. But we expect the protocol to be opened in Bay Shore, Long Island within the next 60 days.
My new office contact number is 631 666 6752
Users browsing this forum: No registered users